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Abstract:  
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Griseofulvin is a fungal metabolite and antifungal drug used for the treatment 
of dermatophytosis in both humans and animals. Recently, griseofulvin and its analogues have 
attracted renewed attention due to reports of their potential anticancer effects. In this study 
griseofulvin (1) and related analogues (2–6, with 4 being new to literature) were isolated 
from Xylaria cubensis. Six fluorinated analogues (7–12) were synthesized, each in a single step 
using the isolated natural products and Selectflour, so as to examine the effects 
of fluorine incorporation on the bioactivities of this structural class. The isolated and synthesized 
compounds were screened for activity against a panel of cancer cell lines (MDA-MB-435, MDA-
MB-231, OVCAR3, and Huh7.5.1) and for antifungal activity against Microsporum gypseum. A 
comparison of the chemical space occupied by the natural and fluorinated analogues was carried 
out by using principal component analysis, documenting that the isolated and fluorinated 
analogues occupy complementary regions of chemical space. However, the most active 
compounds, including two fluorinated derivatives, were centered around the chemical space that 
was occupied by the parent compound, griseofulvin, suggesting that modifications must preserve 
certain attributes of griseofulvin to conserve its activity. 
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Griseofulvin is a fungal metabolite and antifungal drug used for the treatment of dermatophytosis in both
humans and animals. Recently, griseofulvin and its analogues have attracted renewed attention due to
reports of their potential anticancer effects. In this study griseofulvin (1) and related analogues (2–6, with
4 being new to literature) were isolated from Xylaria cubensis. Six fluorinated analogues (7–12) were syn-
thesized, each in a single step using the isolated natural products and Selectflour, so as to examine the
effects of fluorine incorporation on the bioactivities of this structural class. The isolated and synthesized
compounds were screened for activity against a panel of cancer cell lines (MDA-MB-435, MDA-MB-231,
OVCAR3, and Huh7.5.1) and for antifungal activity against Microsporum gypseum. A comparison of the
chemical space occupied by the natural and fluorinated analogues was carried out by using principal
component analysis, documenting that the isolated and fluorinated analogues occupy complementary
regions of chemical space. However, the most active compounds, including two fluorinated derivatives,
were centered around the chemical space that was occupied by the parent compound, griseofulvin, sug-
gesting that modifications must preserve certain attributes of griseofulvin to conserve its activity.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bioactive secondary metabolites have had a long history in
medicine, as they provide privileged scaffolds for drug discov-
ery.1–4 As testament to this, from 1981 to 2014 over half of the
new small molecule drugs approved by the U.S. FDA were natural
products or natural product-derived/natural product-inspired.5,6
The success of natural products as source of therapeutic agents is
driven by their biochemical specificity and high chemical diversity,
occupying distinct regions of chemical space that coincide with
clinically relevant areas.2,7
Fungi are one of the most species-rich organisms, second only to
insects, offering a vast resource for discovery of new drug leads. Our
recent collaborative efforts underscore the structural complexityand diversity of fungal metabolites.7–9 As promising compounds
are identified, these structural features are of particular relevance,
as they can be used to stimulate semi-synthetic10,11 approaches
to explore structure-activity relationships and produce new drug
candidates.
The natural product griseofulvin (1, Fig. 1), (2S,60R)-7-chloro-
20,4,6-trimethoxy-60-methyl-3H-spiro[benzofuran-2,10-cyclo-
hexan]-20-ene-3,40-dione, is a potent antifungal drug orally admin-
istered for the treatment of dermatophytosis (i.e., fungal infection
of the skin) in both humans and animals.12–15 Since its isolation
and discovery from a filamentous fungus in 1939,16 most research
has focused on the identification of griseofulvin analogues, either
from nature or synthetically, but to date, only the original com-
pound (1) has been developed into a marketable antifungal drug,
first approved in 1959.13 Recently, there has been a renewed inter-
est in 1 due to its antimitotic and antiproliferative activities against
various types of cancer cells.17–21 Griseofulvin has a mode of action
R1 R2 R3
1 Cl H CH3
2 Cl OH CH3
3 H H CH3
4 H OH CH3
5 H H H 
6 Cl H H 
Fig. 1. Structures of griseofulvin (1) and related analogues (2–6) isolated from
Xylaria cubensis (strain MSX48662).
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dynamics in both fungal and mammalian cells has been pro-
posed.13,22,23 Thus, aside from being an antifungal drug, it may also
be a clinically-viable candidate for cancer chemotherapy.21–26 Due
to these reasons, it was decided that the isolation and semi-synthe-
sis of griseofulvin analogues was worth further investigation.
The introduction of fluorine into a bioactive compound has been
shown to impart a range of effects, often altering physicochemical
profiles by modulating acid/base properties, electronegativity,
lipophilicity, and metabolic stability.27,28 Focusing on these unique
properties, fluorine has been exploited in the design and optimiza-
tion of biologically active molecules.27,29,30 With our interest in late
stage fluorination of secondary metabolites,10 we envisioned the
ability to prepare various fluorinated griseofulvin derivatives. Our
approach hinged on the chemoselective nature of Selectfluor as
an electrophilic fluorinating reagent. Since the starting materials
were the isolated fungal metabolites, it was essential to limit any
side reactions of the vinyl ether or epimerization of the asymmet-
ric centers. We further rationalized that 1, already proven to be a
successful therapeutic, was a good candidate to investigate the
influence of fluorine substitution as a strategy to expand the
medicinally-relevant chemical space of fungal metabolites.
An isolate of the filamentous fungus Xylaria cubensis (strain
MSX48662) was found to be a prolific producer of 1, biosynthesiz-
ing over 100 mg per a single rice-based fermentation culture
grown in a 2.8 L Fernbach flask,31 and thus, it was used for resupply
purposes. Hence, the fungal extract was subjected to further stud-
ies and afforded six compounds, including 1 and structurally
related analogues, four of which were known (2, 3, 5, and 6) and
one of which (4) was new to the literature. Seven additional fluo-
rinated analogues (7, 8a/8b, 9–12) were synthesized using 1, 3
and 4 as starting materials. All 12 compounds were evaluated for
cytotoxicity against cancer cell lines, including human melanoma
cancer cells (MDA-MB-435), human breast cancer cells (MDA-
MB-231), human ovarian cancer cells (OVCAR3), and human hep-
atoma (Huh7.5.1) cells.32 Moreover, the antifungal potency of 1–
12 against Microsporum gypseum was assessed in a disk diffusion
assay. Characterization of the chemical space of the isolated and
synthesized analogues was also carried out by principal compo-
nent analysis to correlate structural modifications with the
observed bioactivities.2. Results and discussion
2.1. Isolation of griseofulvin (1) and related analogues (2–6)
Organic extracts (CHCl3/CH3OH) from the rice-based fermenta-
tion cultures of MSX48662 were partitioned with organic solvents,
subjected to flash chromatography, and were purified using
preparative HPLC to yield griseofulvin (1) and five structurally
related analogues (2–6), with 4 being new to literature. The struc-
tures of compounds 1–3 and 5–6 were established by analysis ofHRESIMS and NMR data, all of which compared favorably to the lit-
erature (See the Supporting Information for spectral data).33,34
Compound 4 was isolated as a white solid. The NMR and HRE-
SIMS data (m/z 335.1119 [M+H]+) both indicated a molecular for-
mula of C17H18O7, corresponding to a difference of an additional
OH (16 Da) relative to 3. The 1H NMR spectrum of 4 (Table S5
and Figs. S4–S6) showed similarities to 3, including signals for a
1,2,3,5-tetrasubstituted aromatic ring, as evidenced by the meta-
coupled aromatic proton signals at dH 6.06 and dH 6.22 (3JHH = 1.1 -
Hz), an isolated olefinic proton, three methoxy groups, as well as a
methyl group. However, it was also clear from these data that the
diastereotopic methylene proton a-H-50 in 3 was replaced with a
hydroxy moiety in 4, thus shifting b-H-50 to the more downfield
region of the spectrum (dH 4.71). The large coupling constant
(3JHH = 12.1 Hz) observed between H-50 and H-60 placed both pro-
tons in trans-diaxial positions, imparting 50-OH and 60-CH3 in equa-
torial positions, analogous to that of 2. Based on these
observations, the configuration at C-50 was established as R. A com-
parison of the observed specific rotation value ([a]D27 +343) of 4
with those for 1 ([a]D27 +340), 2 ([a]D27 +306) and 3 ([a]D27 +386)
revealed that the configurations at C-2 (S) and C-60 (R) of these
compounds were identical. Thus, the structure of compound 4
was established as shown (Fig. 1) and identified as (2S,50R,60R)-7-
dechloro-50-hydroxygriseofulvin.
2.2. Semi-synthesis and structural elucidation of fluorinated analogues
There are a few reports on the fluorination of griseofulvin and
its analogues.35,36 For example, monofluorinated and difluorinated
griseofulvin analogues have been prepared by Taub and co-work-
ers in 1963 and Barton and co-workers in 1972 by electrophilic flu-
orination of griseofulvin using either perchloryl fluoride
(FClO3)37,38 or fluoroxytrifluoromethane (CF3OF),39 two of the ear-
liest electrophilic fluorination reagents. These harsh conditions
resulted in the formation of several mono- and difluorinated prod-
ucts, including reaction of the enol-ether and some gem-difluoro
derivatives. Our goal was to chemoselectively fluorinate ring A of
griseofulvin without affecting the other functional groups, espe-
cially the enol-ether motif. Thus, Selectfluor, was used as the elec-
trophilic fluorination reagent, since it is known to be milder and
typically more chemoselective than other fluorination
reagents.40–42 Indeed, this strategy yielded only ring A fluori-
nated-derivatives; each substrate gave two mono-fluorinated com-
pounds, with fluorination at either C-5 or C-7, which allowed us to
probe the chemical space of these analogues.
Seven fluorinated products (7, 8a/8b, 9–12) were obtained from
Selectfluor reactions with compounds 1, 3, and 4 (Scheme 1). Flu-
orination of compounds 2, 5, and 6 was not attempted due to pau-
city of isolated starting materials from the fungal cultures.
Selectfluor was chosen as the electrophilic fluorinating reagent
and our results exemplify the chemoselectivity of this reagent. Of
the possible reaction pathways, this reagent only fluorinated the
C5 or C7 positions. All of the semi-synthetic products could be the-
oretically synthesized using traditional total synthesis efforts,
however, our approach generated at least two completed ana-
logues per reaction using the isolated compounds as the starting
materials.
Addition of a solution of 1 (dissolved in CH3CN) to a CH3CN
solution of Selectfluor afforded one minor compound (7) and an
inseparable diastereoisomeric mixture of 8a/8b with a ratio of
2:1, as revealed by interpretation of the 1H NMR data (Fig. S14).
The HRMS data for 7 indicated the incorporation of one fluorine
atom with a molecular formula of C17H16ClFO6. A comparison of
the 1H NMR data (Table S8, Fig. S9) of 7 with 1 suggested the
attachment of a fluorine atom into ring A, as evidenced by the
absence of the aromatic H-5 signal. In addition, the methoxy
Scheme 1. Semi-synthesis of fluorinated compounds 7–12 with Selectfluor. The
percent yields were calculated based on isolated product.
Table 1
Cytotoxicity results for the active compounds.a Compounds 2–9 and 11–12 were
inactive (see Table S14).
Compound IC50
MDA-MB-435c MDA-MB-231d OVCAR3e
1 6.4 mM inactive 48.5 mM
10 22.0 mM inactive inactive
Vinblastineb 0.5 nM 8.8 nM 1.8 nM
a A compound was indicated as inactive if no activity was observed at 50 mM.
b Positive control.
c Human melanoma cancer cells.
d Human breast cancer cells.
e Human ovarian cancer cells.
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coupling43 with a coupling constant of JHF = 3.1 Hz for both. Their
chemical shifts were slightly downfield (Dd 0.14–0.22, Fig. S10)
due to their proximity to the F atom at C-5. 19F–13C HMQC data
(Fig. S11) showed a correlation between the fluorine atom and C-
5, which resonated as a doublet at dC 142.9 with a large coupling
constant of 244.3 Hz typical of a 1JCF bond in an aromatic ring,44
further supporting the position of fluorine. Additionally, the dou-
blet signals observed for C-4 (2JCF = 9.0 Hz) and C-6 (2JCF = 12.1 Hz)
corroborate the attachment of fluorine at C-5. Altogether, these
data identify 7 as 5-fluorogriseofulvin, which was previously
reported by Barton and co-workers by the treatment of griseoful-
vin with fluoroxytrifluoromethane.36
The NMR and HRESIMS data (m/z 357.0543 [M+H]+) for com-
pounds 8a/8b supported a molecular formula of C16H14ClFO6. Fol-
lowing the interpretation of edited-HSQC (Fig. S15) and HMBC
(Fig. S16) experiments, the 13C and 1H NMR data (Table S9) were
assignable to 16 carbon atoms consisting of two methoxy groups,
one methyl, three methine (two sp2 and one sp3), one methylene,
and nine non-protonated carbons (three carbonyls, four olefinic
with three of them oxygenated, and two fully substituted carbons).
Comparison of the NMR data between 1 and 8a/8b indicated that
rings B and C of both compounds were identical. However, modifi-
cations were made in ring A of 8a/8b, as the NMR data indicated
oxidation at C-4 to a ketone due to the absence of a methoxy group
and the presence of an extra carbonyl carbon (dC 176.9). The dou-
blet signal observed for H-5 (3JHF = 1.8 Hz) and the doublet signal
observed for 19F (3JHF = 1.8 Hz) indicated the addition of fluorine
to ring A (Fig. S17). The doublet signal (1JCF 253 Hz) observed
for C-7, along with an HMQC correlation between 19F and C-7 (dC
94), suggested the attachment of fluorine to C-7 (Fig. S18). The
assignment of fluorine being at C-7 was further supported by the
doublet splitting patterns observed for C-6 (2JCF = 19.1 Hz) and C-
7a (2JCF = 21.0 Hz). Thus, the structures of the diastereoisomers
were assigned as shown in Scheme 1. We have previously observed
similar reactivity with Selectfluor reactions,10 as have others with
Selectfluor45 and other related reagents.46–52
The reaction of Selectfluorwith 3 afforded twomono-fluorinated
structural isomers 9 (major) and 10 (minor), both with a molecular
formula of C17H17FO6 based on HRESIMS data. Comparison of the 1H
NMR data of 9 (Table S10) and 10 (Table S11) with those of 3 indi-
cated the loss of one aromatic proton signal attributed to H-5 andH-7, respectively. In compound 9, the C-4 methoxy resonance
appearedmore deshielded comparedwith the corresponding signal
in 3 (Dd 0.3), and showed a doublet splitting pattern due to a
through space coupling with the fluorine at C-5 (Figs. S19–20).
Unlike its chloro-analogue (7), this coupling was observed for the
methoxy group at C-4 only, which suggested that, in the preferred
conformer, the methoxy group at C6 in 9 is rotated away from the
fluorine. Likewise, the methoxy groups in compound 10 showed
no through-space coupling with the fluorine, indicated that the
dominant conformation presents the C6 methoxy group away from
the fluorine atom. Alternatively, compound 7 prefers to adopt a
conformation where the methoxy group at C-6 is in close proximity
to the fluorine due to the steric effect imposed by the chlorine
atom.53,54
1H NMR data for compound 9 also showed a doublet at d 6.37
(3JHF = 5.2 Hz), which was assigned to H-7 due to long-range cou-
pling with fluorine (Figs. S19–S20). The correlation detected
between the fluorine and C-5 (dC 139.6, doublet, 1JCF = 237.5 Hz)
in the 19F–13C-HMQC data (Fig. S21) suggested the connection of
fluorine to position 5. The attachment of fluorine at C-5 was further
corroborated by the small doublet splitting observed for C-4
(2JCF = 8.8 Hz) and C-6 (2JCF = 11.3 Hz), establishing the structure
of 9 as 5-fluoro-7-dechlorogriseofulvin. The structure of 10 was
established in an analogous manner and was identified as 7-flu-
oro-7-dechlorogriseofulvin (Table S11; Figs. S24–S28), which was
previously reported by Taub and co-workers.35
As was the case for 3, reaction of compound 4 with Selectfluor
yielded two mono-fluorinated structural isomers, 11 and 12. The
HRESIMS data served to verify the number of incorporated fluorine
atoms in the compounds, while the NMR data was analyzed in the
same manner as 9 (Tables S12–S13; Figs. S29–S38). This exercise
established the structures of 11 and 12 as the 50-OH analogues of
compounds 9 and 10, respectively.2.3. Biological evaluation
Griseofulvin (1) and all 11 analogues (2–12) were evaluated for
their cytotoxic activity against three different cancer cell lines,
specifically MDA-MB-435, MDA-MB-231, and OVCAR3 (Tables 1
and S14). Compounds 1 and 10 had moderate to minimal cytotox-
icity, with IC50 values ranging from approximately 6–50 mM, and
other compounds were inactive at a 50 mM concentration. As a
complementary dataset, we also tested 1–12 against human hep-
atoma Huh7.5.1 cells; the results were in agreement, indicating
cytotoxic activity (ranging from approximately 10–25 lM) for 1
and 10 (Fig. S39).
All compounds (1–12) were also tested in an antifungal assay
against Microsporum gypseum, a dermatophyte that causes tinea
capitis, tinea corpus, and other fungal infections of the skin.55,56
As shown in Tables 2 and S15, compound 10 retained the activity
of 1, while 7 showed a slight decrease in activity. Compound 10
Table 2
Antifungal results against Microsporum gypseum for the active
compounds.a Results for the other compounds in this study are
shown in Table S15.
Compound Zone of Inhibition (mm)a
1b 35 ± 1
7 23 ± 1
10 34 ± 1
a Mean diameter of inhibition zones at 25 mg/disk expressed as
the mean of four replicates ± standard deviation.
b Positive control.
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plant pathogen Botrytis alii,35 but its activity against dermato-
phytes, particularly M. gypseum, has not been reported. The anti-
fungal activity of 7 has not been reported previously.2.4. Principal component analysis
The introduction of fluorine into molecules often results in sig-
nificant changes in their molecular properties and biological activ-
ities.30,57 The small atomic size, very high electronegativity, and
low polarizability of the fluorine atom are just a few of the charac-
teristics that can have important consequences in a lead optimiza-
tion program, particularly one focused on modifying privileged
scaffolds. To compare the distribution in chemical space between
the natural analogues (1–6) versus the fluorinated analogues (7–
12), and identify structural features important to maintain griseo-
fulvin’s cytotoxic and antifungal activities, principal component
analysis (PCA) was performed. Eleven molecular properties that
describe the electron distribution, molecular surface, and solubility
of the compounds were used in an attempt to emphasize the vari-
ation given by the addition of a fluorine. The first two principal
components (PC1, PC2) retrieved 68% of the covariance, whereas
the first three principal components (PC1–PC3) retrieved 87% ofFig. 2. Visual representation of the chemical space of griseofulvin (1, red), structurally re
blue). This 3D plot was generated with the principal component analysis of 11 descriptors
affinity (EA (eV)) and electrotopological state (Estate) had the highest contribution to the
the highest contribution to the second principal component (PC2). Dipole moment hadthe covariance. Interestingly, two electronic descriptors, namely
electron affinity (EA (eV)) and electrotopological state (Estate),
had the highest contribution to PC1, while QPlogS, a descriptor
related to the solubility of the compounds, had the highest contri-
bution to PC2. The dipole moment of the molecule, an electronic
descriptor, had the highest contribution to PC3. These results fur-
ther emphasized that the addition of a fluorine atom changed
mostly the electronic distribution within the molecules, as
reflected in the clear separation in the PCA of the fluorinated vs.
non-fluorinated analogues of griseofulvin (Fig. 2).
The 3D representation of the chemical space of 1–12 revealed
several interesting features (Fig. 2). For example, the 3D plot
showed that the fungal metabolites clustered together, occupying
a distinct region in the chemical space different from the fluori-
nated analogues, further illustrating that fluorine incorporation
modified the molecular properties of the analogues. Additionally,
fluorinated analogues 7, 9, and 10 were closer to griseofulvin in
chemical space, suggesting that these analogues had similar elec-
tron distribution, solubility, and surface characteristics, which
could indicate that these compounds had similar bioactivities. Sim-
ilar results were observed on the 2D plot with PC1 and PC2
(Fig. S40). The association between chemical similarity (as visual-
ized by PCA using the set of descriptors) and similarity in bioassay
results held true for 7 and 10 but not for 9. Compound 9 appears to
be an activity cliff,58 that is, a compound with similar structure to
1, 7 and 10 but different biological activity. Further inspection of
the structure of the molecules indicates that compound 9 lacks
the halogen atom at the C-7 position. This suggests that the highly
electronegative nature and geometric size of a halogen at C-7 of
ring A appears to be an important feature of 1, 7 and 10 in order
to retain its biological effect. The biological activity observed for
7 can be rationalized given that the van der Waals radius of a flu-
orine atom (1.47 Å) is only slightly larger than that of hydrogen
(1.20 Å). For compound 7, the replacement of the hydrogen atom
with a fluorine atom at C-5 did not impart a large change in molec-
ular volume or the overall structure of the compound, thuslated fungal analogues (2–6, green) and fluorinated semisynthetic derivatives (7–12,
. The first three principal components recovered 87% of the covariance. The electron
first principal component (PC1), while the predicted aqueous solubility (QPlogS) had
the highest contribution to the third principal component (PC3).
Fig. 3. A 2D visual representation of the chemical space of griseofulvin (1, red), structurally related fungal analogues (2–6, green) and fluorinated semisynthetic derivatives
(7–12, blue) generated using two descriptors, predicted aqueous solubility (QPlogS; y-axis) and electron affinity [EA(Ev); x-axis].
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atom, particularly at the C-7 position (ortho relative to the C-6
methoxy group), may also impart steric constraints and/or electro-
static effects that may be necessary for optimum molecular recog-
nition between the compound and an active site/receptor. A
fluorine atom at C-7, instead of chlorine, as was the case in com-
pound 10, may induce a similar electronic effect on the compound.
The difference in electronegativity between the fluorine and car-
bon creates a large dipole moment in this bond, contributing to
the overall electronic nature of the molecule, and this could lead
to specific interactions with an active site/receptor. Although 10
retains the antifungal activity and cytotoxicity of 1, a decrease in
potency was observed, which may be explained by a decrease in
the steric bulk in 10 at C-7 due to a difference in van der Waals
radius between a fluorine atom (1.47 Å) and chlorine (1.75 Å).
A 2D plot of predicted aqueous solubility (QPlogS) and electron
affinity (eV) similarly illustrated the variance in the distribution of
the analogues across the chemical space (Fig. 3). The addition of
fluorine to the griseofulvin analogues increased the electron affin-
ity of the compounds, and this was manifested in chemical space as
separating the fluorinated analogues from the natural secondary
metabolites. Compound 7, which is the C-5 fluorinated derivative
of 1, shared similar molecular properties in chemical space as 1.
Moreover, Figs. 2 and 3 illustrate that analogues 8a/8b, which lost
the aromaticity at ring A, were in a different region of chemical
space, far from the rest of the analogues. It was observed that
the fluorinative dearomatization of ring A in 8a/8b significantly
altered the properties of these compounds compared to griseoful-
vin (1). These changes could explain in part why 8a/8b were inac-
tive. Overall, the addition of fluorine or a hydroxy group to the A or
C rings, respectively improved the predicted solubility (Fig. 3).3. Conclusion
In summary, griseofulvin (1) and five analogues (2–6), with 4
being new to the literature, were isolated from X. cubensis. Addi-
tionally, a series of fluorinated analogues (7–12) were synthesized,
each requiring only a single step from the isolated natural products
using Selectfluor. The chemoselective nature of Selectfluor allowed
for direct, site-specific mutation of the natural products without
the use of protecting groups or other redox-modifications. Of the
synthesized analogues, 8a/8b, 9, 11, 12 are reported for the first
time. All compounds were tested against the dermatophyteM. gyp-seum and in cytotoxicity assays against human melanoma cancer
cells (MDA-MB-435), human breast cancer cells (MDA-MB-231),
human ovarian cancer cells (OVCAR3), and human hepatoma cells
(Huh7.5.1). Of the analogues, 10 retained the activity of 1 against
M. gypseum, while 7 displayed decreased potency. Only compound
10 exhibited cytotoxic activity, but was less active compared to 1
against the MDA-MB-231 cells. To visualize the differences in the
molecular and physicochemical properties generated by the addi-
tion of a single fluorine atom to the fungal secondary metabolites,
PCA was used based on descriptors related to the electron distribu-
tion, solubility and molecular surface of the compounds. These
descriptors captured the variation in the molecular properties
and demonstrated that fluorinated analogues occupy a different
region of chemical space than the fungal secondary metabolites.
In addition, it was observed that the presence of a halogen in C-7
is important to maintain the biological activity for this class of
compounds, as was observed for compounds 7 and 10. These two
compounds were close to griseofulvin in the chemical space,
results that were consistent with the bioassay testing. This sug-
gests that PCA can be a useful tool to visualize and guide the anal-
ysis of relevant structure-activity relationships. Taken together,
these results demonstrate the synergistic opportunity of combin-
ing natural products chemistry, chemoselective semi-synthetic
methods, and cheminformatics to rapidly develop and evaluate
new, structurally-complex chemical entities from privilege
scaffolds.4. Experimental section
4.1. General experimental procedure
All solvents and chemicals were purchased from standard sup-
pliers and were used without any further purification. The NMR
data were collected using either a JEOL ECS-400 spectrometer
(JEOL USA, Inc.) operating at 400 MHz for 1H and 100 MHz for
13C, and equipped with JEOL normal geometry broadband Royal
probe; or a JEOL ECA-500 spectrometer (JEOL USA, Inc.) operating
at 500 MHz for 1H and 125 MHz for 13C; or an Agilent 700 MHz
NMR spectrometer (Agilent Technologies, Inc., Santa Clara, CA,
USA) operating at 700 MHz for 1H and 175 MHz for 13C, and
equipped with a cryoprobe. NMR chemical shift values were refer-
enced to residual solvent signals for CDCl3 (dH/dC 7.26/77.2). Data
for 1H NMR are reported as follows: chemical shift (d ppm),
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septet, m = multiplet), coupling constant (Hz), and integration;
whereas 13C NMR analyses were reported in terms of chemical
shift. HRESIMS data were obtained using a Thermo QExactive Plus
mass spectrometer (ThermoFisher, San Jose, CA, USA) with an elec-
trospray ionization source coupled with a Waters Acquity ultraper-
formance liquid chromatography (UPLC) system (Waters Corp.).
The UPLC separation was performed using an Acquity BEH C18 col-
umn (50 mm  2.1 mm i.d., 1.7 mm) equilibrated at 40 C and a
flow rate set at 0.3 mL/min. The mobile phase consisted of a linear
CH3CN/H2O (acidified with 0.1% HCOOH) gradient starting at 15%
CH3CN to 100% CH3CN over 8 min. The mobile phase was held
for another 1.5 min at 100% CH3CN before going back to the start-
ing conditions. The HPLC separations were performed using Varian
ProStar HPLC system connected to a ProStar 335 photodiode array
detector (PDA) with UV detection set at 210 nm and 254 nm.
Preparative reversed phase HPLC purification of samples was per-
formed on a Phenomenex Gemini-NX C18 (5 lm; 250  21.2 mm)
column using a 21 mL/min flow rate of the mobile phase consisting
of a mixture of CH3CN and H2O (with 0.1% HCOOH). Flash column
chromatography was carried out with a Teledyne ISCO Combiflash
Rf connected to an ELSD and PDA detectors with UV detection set
at 200–400 nm. Optical rotation data were acquired on a Rudolph
Research Autopol III polarimeter (Rudolph Research Analytical,
Flanders, NJ, USA). The UV data were acquired using a Varian Cary
100 Bio UV–Vis spectrophotometer (Varian Inc., Walnut Creek, CA,
USA). The optical density (OD) at 600 nm was acquired using
Thermo ScientificTM GenesysTM 20.4.2. Fungal strain identification
Fungal strain MSX48662 was isolated from cedar wood col-
lected in Little Rock, Arkansas and was identified using morpholog-
ical and molecular methods59 as described in detail previously.31
Based on morphological characterization and molecular phyloge-
netic analysis, strain MSX48662 was identified as Xylaria cubensis
(Sordariomycetes, Ascomycota). The sequence data for the strain
utilized in the study was deposited in GenBank under accession
number KX229783.4.3. Fermentation, extraction, and isolation of natural products (1–6)
The fermentation of fungal strain MSX48662 was performed
using procedures described previously with slight modifica-
tions.60–62 Briefly, a fresh culture of the fungus was grown on a
malt extract slant. Subsequently, a small agar plug with mycelium
was inoculated in a liquid medium consisting of 2% soy peptone, 2%
dextrose, and 1% yeast extract (YESD media). This was followed by
incubation for approximately 7 days at room temperature (22 C)
with shaking. The seed culture was used to inoculate a Fernbach
flask (2.8 L) containing rice (150 g) and H2O (300 mL) and grown
at rt for a period of 20 days.
The solid fermentation culture was extracted by addition of 1:1
CH3OH/CHCl3 (500 mL), followed by agitation for 16 h, and filtered.
To the filtrate, 900 mL of CHCl3 and 1500 mL of H2O were added,
and stirred for 30 min. The biphasic solution was partitioned, and
the organic phase was collected and dried in vacuo. The resulting
dried extract was further partitioned between CH3OH/CH3CN
(1:1, 300 mL) and hexanes (300 mL) to obtain fractions weighing
2 g and 4 g, respectively. The CH3OH/CH3CN soluble partition was
then adsorbed on Celite 545, and subjected to silica flash chro-
matography on a 24 g RediSep Rf Gold Si-gel column, eluting with
use of a gradient solvent system of hexane/CHCl3/CH3OH at a flow
rate of 35 mL/min over 71 column volumes for a duration of
68 min to give 100 fractions each containing 25 mL. The resultingfractions were then pooled according to their ELSD and UV profiles,
which resulted to 16 subfractions.
Fraction 6 (230 mg) was subjected to preparative reversed-
phase HPLC eluting with a linear gradient from 30% to 50% CH3CN
in H2O (0.1% HCOOH) over 30 min to afford compound 1 (92 mg,
tR = 20.0 min), 2 (1.0 mg, tR = 15.5 min), 3 (64 mg, tR = 16.5 min),
and 4 (15 mg, 12.5 min). Fraction 7 (115 mg) was purified using
the same preparative HPLC conditions yielding more of compounds
2 (11 mg, tR = 15.5 min) and 4 (17 mg, tR = 12.5 min). Fraction 9
(250 mg) was similarly chromatographed but using a linear gradi-
ent from 20% to 40% CH3CN in H2O (0.1% HCOOH) over 15 min fol-
lowed by an increase in the gradient to 80% CH3CN to afford
compounds 5 (1.9 mg, tR = 17.0 min) and 6 (2.7 mg, tR = 21.5 min).4.3.1. (2S,60R)-7-Chloro-20,4,6-trimethoxy-60-methyl-3H-spiro
[benzofuran-2,10-cyclohexan]-20-ene-3,40-dione; griseofulvin (1)
White solid; [a]D27 +340 (c 0.1, CHCl3); UV (MeOH) kmax (loge)
236 (4.4), 291 (4.4), 331 (3.7) nm; 1H NMR (400 MHz, CDCl3)
d = 0.96 (d, J = 6.8 Hz, 3H), 2.42 (dd, J = 16.8 Hz, 4.6 Hz, 1H), 2.84
(m, 1H), 3.03 (dd, J = 16.8 Hz, 13.4 Hz, 1H), 3.61 (s, 3H), 3.98 (s,
3H), 4.03 (s, 3H), 5.53 (s, 1H), 6.13 (s, 1H); 13C NMR (100 MHz,
CDCl3) d = 14.4, 36.5, 40.1, 56.5, 56.8, 57.1, 89.5, 90.9, 97.3, 105.0,
105.2, 157.9, 164.7, 169.6, 170.9, 192.6, 197.2 (See Table S2 and
Fig. S1); HRESIMS m/z 353.0781 [M+H]+ (calc’d for C17H18ClO6,
353.0786).4.3.2. (2S,50R,60R)-7-Chloro-50-hydroxy-20,4,6-trimethoxy-60-methyl-
3H-spiro[benzofuran-2,10-cyclohexan]-20-ene-3,40-dione; 50-
hydroxygriseofulvin (2)
White solid; [a]D27 +306 (c 0.1, MeOH); UV (MeOH) kmax (loge)
236 (4.2), 291 (4.2), 331 (3.6) nm; 1H NMR (700 MHz, CDCl3)
d = 1.11 (d, J = 6.7 Hz, 3H), 2.64 (dq, J = 12.2 Hz, 6.7 Hz, 1H), 3.65
(s, 3H), 3.99 (s, 3H), 4.04 (s, 3H), 4.68 (d, J = 12.2 Hz, 1H), 5.61 (s,
1H), 6.14 (s, 1H); 13C NMR (175 MHz, CDCl3) d = 11.1, 43.6, 56.6,
57.1, 57.2, 71.5, 89.7, 91.2, 97.4, 101.8, 105.2, 158.0, 165.0, 169.8,
171.5, 192.6, 197.5 (See Table S3 and Fig. S2); HRESIMS m/z
369.0738 [M+H]+ (calc’d for C17H18ClO7, 369.0736).4.3.3. (2S,60R)-20,4,6-Trimethoxy-60-methyl-3H-spiro[benzofuran-2,10-
cyclohexan]-20-ene-3,40-dione; 7-dechlorogriseofulvin (3)
White solid; [a]D27 +386 (c 0.1, MeOH); UV (MeOH) kmax (loge)
239 (4.4), 287 (4.4), 321 (3.8) nm; 1H NMR (400 MHz, CDCl3)
d = 0.94 (d, J = 6.6 Hz, 3H), 2.39 (dd, J = 16.8 Hz, 4.7 Hz, 1H), 2.74
(m, 1H), 3.03 (dd, J = 16.8 Hz, 13.4 Hz, 1H), 3.61 (s, 3H), 3.89 (s,
3H), 3.90 (s, 3H), 5.53 (s, 1H), 6.03 (d, J = 1.9 Hz, 1H), 6.23 (d,
J = 1.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) d = 14.4, 36.7, 40.2,
56.2, 56.2, 56.8, 88.6, 90.0, 93.5, 104.4, 104.9, 159.2, 170.5, 171.5,
176.2, 192.7, 197.6 (Table S4 and Fig. S3); HRESIMS m/z
319.1175 [M+H]+ (calc’d for C17H19O6, 319.1176).4.3.4. (2S,50R,60R)-50-Hydroxy-20,4,6-trimethoxy-60-methyl-3H-spiro
[benzofuran-2,10-cyclohexan]-20-ene-3,40-dione; 7-dechloro-50-
hydroxygriseofulvin (4)
White solid; [a]D27 +343 (c 0.1, MeOH); UV (solvent) kmax (loge)
230 (4.4), 288 (4.4), 321 (3.7) nm; 1H NMR (400 MHz, CDCl3)
d = 1.11 (d, J = 6.6 Hz, 3H), 2.55 (dq, J = 12.1 Hz, 6.6 Hz, 1H), 3.66
(s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 4.71 (d, J = 12.1 Hz, 1H), 5.61 (s,
1H), 6.06 (d, J = 1.1 Hz, 1H), 6.22 (d, J = 1.1 Hz, 1H); 13C NMR
(100 MHz, CDCl3) d = 11.2, 43.9, 56.3, 56.3, 57.1, 71.5, 88.6, 90.5,
93.7, 101.7, 104.4, 159.3, 170.8, 172.1, 176.3, 192.6, 197.8. (See
Table S5 and Figs. S4–S6); HRESIMS m/z 335.1119 [M+H]+ (calc’d
for C17H19O7, 335.1125).
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[benzofuran-2,10-cyclohexan]-20-ene-3,40-dione; 6-O-desmethyl-7-
dechlorogriseofulvin (5)
White solid; [a]D27 +221 (c 0.1, MeOH); UV (solvent) kmax (loge)
248 (4.3), 290 (4.2), 322 (4.2) nm; 1H NMR (400 MHz, CDCl3)
d = 0.97 (d, 6.7 Hz, 3H), 2.43 (dd, J = 16.7 Hz, 4.8 Hz, 1H), 2.76
(dqd, J = 13.2 Hz, 6.7 Hz, 4.8 Hz, 1H), 3.08 (dd, J = 16.7 Hz,
13.2 Hz, 1H), 3.64 (s, 3H), 3.90 (s, 3H), 5.55 (s, 1H), 6.05 (d,
J = 1.9 Hz, 1H), 6.20 (d, J = 1.9 Hz, 1H); 13C NMR (100 MHz, CDCl3)
d = 14.4, 36.7, 40.1, 56.3, 56.9, 90.0, 91.7, 93.6, 104.1, 104.7,
159.9, 167.9, 172.2, 175.8, 192.6, 198.4 (See Table S6 and
Fig. S7); HRESIMS m/z 305.1032 [M+H]+ (calc’d for C16H17O6,
305.1020).
4.3.6. (2S,60R)-7-Chloro-6-hydroxy-20,4-dimethoxy-60-methyl-3H-
spiro[benzofuran-2,10-cyclohexan]-20-ene-3,40-dione; 6-O-desmethyl-
7-griseofulvin (6)
White solid; [a]D27 +278 (c 0.1, MeOH); UV (solvent) kmax (loge)
243 (4.3), 288 (4.3), 347 (3.7) nm; 1H NMR (400 MHz, CDCl3)
d = 0.97 (d, J = 6.7 Hz, 3H), 2.44 (dd, J = 16.6 Hz, 4.7 Hz, 1H), 2.83
(dqd, J = 13.3 Hz, 6.7 Hz, 4.7 Hz, 1H), 3.04 (dd, J = 16.6 Hz,
13.3 Hz, 1H), 3.63 (s, 3H), 3.92 (s, 3H), 5.55 (s, 1H), 6.25 (s, 1H);
13C NMR (100 MHz, CDCl3) d = 14.4, 36.5, 40.1, 56.6, 56.8, 91.2,
93.6, 95.2, 105.0, 105.4, 158.0, 161.8, 169.9, 170.7, 192.2, 197.2.
(See Table S7 and Fig. S8); HRESIMS m/z 339.0646 [M+H]+ (calc’d
for C16H16ClO6, 339.0630).
4.4. General fluorination procedure with Selectfluor
To an ice-cold acetonitrile solution of the natural product
(0.02 M) was slowly added a freshly prepared acetonitrile solution
of Selectfluor (0.02 M). The reaction mixture was allowed to stir at
0 C for 4 h and then heated to 50 C and monitored by HPLC. After
24 h, the reaction mixture was cooled to room temperature and the
solvent was removed in vacuo.
4.4.1. Fluorination of griseofulvin (1)
Griseofulvin (1) (10.0 mg, 0.028 mmol) and Selectfluor
(15.1 mg, 0.043 mmol) were reacted via the general method. The
residue was purified by preparative HPLC eluting with a linear gra-
dient from 40% to 60% CH3CN in H2O (0.1% HCOOH) over 30 min to
obtain 7 (tR = 19 min) and 8a/8b (tR = 13 min).
4.4.1.1. (2S,60R)-7-Chloro-5-fluoro-20,4,6-trimethoxy-60-methyl-3H-
spiro[benzofuran-2,10-cyclohexan]-20-ene-3,40-dione; 5-Fluorogriseo-
fulvin (7). White solid; [a]D27 +290 (c 0.1, MeOH); 1.0 mg (10%
yield); white solid; 1H NMR (400 MHz, CDCl3) d = 0.95 (d,
J = 6.7 Hz, 3H), 2.45 (dd, J = 16.7 Hz, 4.4 Hz, 1H), 2.85 (dqd,
J = 13.3 Hz, 6.7 Hz, 4.4 Hz, 1H), 2.98 (dd, J = 16.7 Hz, 13.3 Hz, 1H),
3.64 (s, 3H), 4.17 (d, J = 3.1 Hz, 3H), 4.20 (d, J = 3.1 Hz, 3H), 5.56
(s, 1H). 13C NMR (100 MHz, CDCl3) d = 14.4, 36.6, 40.0, 56.9, 62.1
(d, J = 7.0 Hz), 62.6 (d, J = 6.0 Hz), 90.6, 103.4, 105.2, 108.0, 142.9
(d, J = 244.3 Hz), 144.7 (d, J = 9.0 Hz), 153.9 (d, J = 12.1 Hz), 164.9,
170.5, 193.5 (d, J = 4.0 Hz), 196.8. 19F NMR (470 MHz, CDCl3)
d = 155.5 (sept. J = 3.1 Hz) (See Table S8 and Figs. S9–S13); HRE-
SIMS m/z 371.0696 [M+H]+ (calc’d for C17H17ClFO6 371.0692).
4.4.1.2. (2S,60R)-7-Chloro-5-fluoro-20,4,6-trimethoxy-60-methyl-3H-
spiro[benzofuran-2,10-cyclohexan]-20-ene-3,40-dione (8a/8b). Glassy
yellow; 2.3 mg (Isolated as a diastereoisomeric mixture of the
two compounds with a 2:1 ratio) [a]D27 +194 (c 0.1, MeOH) (23%
yield); 8a:1H NMR (400 MHz, CDCl3) d = 1.00 (d, J = 6.3 Hz, 3H),
2.46 (dd, J = 16.1 Hz, 4.2 Hz, 1H), 2.89 (m, 1H), 2.97 (m, 1H), 3.69
(s, 3H), 3.94 (s, 3H), 5.55 (d, J = 1.8 Hz, 1H), 5.58 (s, 1H). 13C NMR
(100 MHz, CDCl3) d = 14.1, 36.1, 39.7, 57.1, 57.8, 94.1, 94.1 (d,
J = 252.3), 102.0 (d, J = 2.0 Hz), 105.4, 110.1 (d, J = 3.0 Hz), 162.8(d, J = 19.1 Hz), 168.1, 176.9 (d, J = 2.0 Hz), 185.3 (d, J = 21.0 Hz),
191.8, 195.8. 19F NMR (470 MHz, CDCl3) d = 126.4 (d, J = 1.8 Hz).
8b: 1H NMR (400 MHz, CDCl3) d = 1.06 (d, J = 6.3 Hz, 3H), 2.46
(dd, J = 16.1 Hz, 4.2 Hz, 1H), 2.95 (m, 1H), 2.97 (m, 1H), 3.67 (s,
3H), 3.94 (s, 3H), 5.55 (d, J = 1.8 Hz, 1H), 5.58 (s, 1H). 13C NMR
(100 MHz, CDCl3) d = 14.1, 36.5, 39.7, 57.2, 57.8, 94.0 (d,
J = 254.3), 94.1, 102.0 (d, J = 2.0 Hz), 105.5, 110.0 (d, J = 3.0 Hz),
162.8 (d, J = 19.1 Hz), 167.7, 176.9 (d, J = 2.0 Hz), 185.4 (d,
J = 21.0 Hz), 191.7, 195.8. 19F NMR (470 MHz, CDCl3) d = 127.5
(d, J = 1.8 Hz) (See Table S9 and Figs. S14–S18); HRESIMS m/z
357.0543 [M+H]+ (calc’d for C16H15ClFO6 357.0536).
4.4.2. Fluorination of 7-dechlorogriseofulvin (3)
7-Dechlorogriseofulvin (3) (7.0 mg, 0.022 mmol) and Selectfluor
(11.7 mg, 0.033 mmol) were reacted via the general method. The
residue was purified by preparative HPLC eluting with a linear gra-
dient from 30% to 50% CH3CN in H2O (0.1% HCOOH) over 30 min to
obtain compounds 9 (tR = 21 min), and 10 (tR = 18 min).
4.4.2.1. (2S,60R)-5-Fluoro-20,4,6-trimethoxy-60-methyl-3H-spiro[ben-
zofuran-2,10-cyclohexan]-20-ene-3,40-dione; 5-Fluoro-7-dechloro-
griseofulvin (9). White solid; [a]D27 +289 (c 0.1, MeOH); 2.3 mg
(33% yield); 1H NMR (500 MHz, CDCl3) d = 0.95 (d, J = 6.9 Hz, 3H),
2.75 (dd, J = 17.2 Hz, 4.6 Hz, 1H), 2.75 (m, 1H), 3.02 (dd,
J = 17.2 Hz, 13.2 Hz, 1H), 3.63 (s, 3H), 3.98 (s, 3H), 4.20 (d,
J = 3.3 Hz, 3H), 5.55 (s, 1H), 6.37 (d, J = 5.2 Hz, 1H). 13C NMR
(125 MHz, CDCl3) d = 14.4, 36.7, 40.1, 56.8, 57.0, 62.1 (d,
J = 7.5 Hz), 89.8, 90.0, 105.0, 105.5, 139.6 (d, J = 237.5 Hz), 145.0
(d, J = 8.8 Hz), 158.6 (d, J = 11.3 Hz), 170.4, 171.1, 193.4, 197.2. 19F
NMR (470 MHz, CDCl3) d = 163.0 (m) (See Table S10 and
Fig. 19–23); HRESIMS m/z 337.1080 [M+H]+ (calc’d for C17H18FO6
337.1082).
4.4.2.2. (2S,60R)-7-Fluoro-20,4,6-trimethoxy-60-methyl-3H-spiro[ben-
zofuran-2,10-cyclohexan]-20-ene-3,40-dione; 7-Fluoro-7-dechloro-
griseofulvin (10). White solid; [a]D27 +230 (c 0.1, MeOH); 1.3 mg
(19% yield); 1H NMR (700 MHz, CDCl3) d = 0.98 (d, J = 6.7 Hz, 3H),
2.43 (dd, J = 17.2 Hz, 4.8 Hz, 1H), 2.81 (m, 1H), 3.03 (dd,
J = 17.2 Hz, 13.4 Hz, 1H), 3.62 (s, 3H), 3.95 (s, 3H), 4.02 (s, 3H),
5.54 (s, 1H), 6.09 (d, J = 5.2 Hz, 1H). 13C NMR (175 MHz, CDCl3)
d = 14.4, 36.6, 40.2, 56.5, 56.8, 57.3, 90.1, 91.0, 105.0, 105.0, 132.4
(d, J = 238.0 Hz), 154.7 (d, J = 1.8 Hz), 157.4 (d, J = 7.0 Hz), 160.3
(d, J = 8.8 Hz), 170.9, 192.4 (d, J = 2.4 Hz), 197.1. 19F NMR
(470 MHz, CDCl3) d = 171.3 (d, J = 5.2 Hz) (See Table S11 and
Figs. S24–S28); HRESIMS m/z 337.1079 [M+H]+ (calc’d for
C17H18FO6 337.1082).
4.4.3. Fluorination of 7-dechloro-50-hydroxygriseofulvin (4)
7-Dechloro-50-hydroxygriseofulvin (4) (6.2 mg, 0.018 mmol)
and Selectfluor (9.8 mg, 0.027 mmol) were reacted via the general
method. After purification using preparative HPLC eluting with a
linear gradient from 30% to 50% CH3CN in H2O (0.1% HCOOH) over
30 min to obtain compounds 11 (tR = 16 min), and 12 (tR = 14 min).
4.4.3.1. (2S,50R,60R)-5-Fluoro-50-hydroxy-20,4,6-trimethoxy-60-methyl-
3H-spiro[benzofuran-2,10-cyclohexan]-20-ene-3,40-dione; 5-Fluoro-50-
hydroxy-7-dechlorogriseofulvin (11). White solid; [a]D27 +240
(c 0.05, MeOH); 1.7 mg (27% yield); 1H NMR (700 MHz, CDCl3)
d = 1.10 (d, J = 6.9 Hz, 3H), 2.54 (dq, J = 12.0 Hz, 6.9 Hz, 1H), 3.67
(s, 3H), 3.98 (s, 3H), 4.21 (d, J = 3.6 Hz, 3H), 4.67 (d, J = 12.0 Hz,
1H), 5.61 (s, 1H), 6.36 (d, J = 5.4 Hz, 1H). 13C NMR (175 MHz, CDCl3)
d = 11.1, 43.7, 57.1, 57.1, 62.1 (d, J = 6.7 Hz), 71.4, 89.1, 90.4, 101.9,
105.5 (d, J = 1.4 Hz), 139.6 (d, J = 241.6 Hz), 145.1 (d, J = 7.9 Hz),
158.9 (d, J = 11.2 Hz), 170.5, 171.7, 193.4 (d, J = 3.3 Hz), 197.5. 19F
NMR (470MHz, CDCl3) d =162.7 (dq, J = 5.4 Hz, 3.6 Hz)
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(calc’d for C17H18FO7 353.1031).
4.4.3.2. (2S,50R,60R)-7-Fluoro-50-hydroxy-20,4,6-trimethoxy-60-methyl-
3H-spiro[benzofuran-2,10-cyclohexan]-20-ene-3,40-dione; 7-Fluoro-50-
hydroxy-7-dechlorogriseofulvin (12). White solid; [a]D27 +270
(c 0.03, MeOH); 1.0 mg (16% yield); 1H NMR (700 MHz, CDCl3)
d = 1.13 (d, J = 6.3 Hz, 3H), 2.60 (dq, J = 12.0 Hz, 6.3 Hz, 1H), 3.66
(s, 3H), 3.95 (s, 3H), 4.03 (s, 3H), 4.68 (d, J = 12.0 Hz, 1H), 5.61
(s, 1H), 6.10 (d, J = 5.1 Hz, 1H); 13C NMR (175 MHz, CDCl3) d = 11.1,
43.7, 56.6, 57.1, 57.3, 71.4, 90.2, 91.2, 101.8, 104.9, 132.2
(d, J = 237.0 Hz), 154.8 (d, J = 1.8 Hz), 157.6 (d, J = 8.8 Hz), 160.3 (d,
J = 10.5 Hz), 171.5, 192.4 (d, J = 2.7 Hz), 197.4. 19F NMR (470 MHz,
CDCl3) d = 171.1 (d, J = 5.1 Hz) (See Table S13 and Figs. S34–38);
HRESIMSm/z 353.1022 [M+H]+ (calc’d for C17H18FO7 353.1031).
4.5. Cytotoxicity assay
Human melanoma cancer cells (MDA-MB-435), human breast
cancer cells (MDA-MB-231) and human cancer cells (OVCAR3)
were procured from the American Type Culture Collection (Manas-
sas, VA). The cell lines were cultivated in RPMI 1640 medium, sup-
plemented with fetal bovine serum (10%), penicillin (100 units/
mL), and streptomycin (100 mg/mL); and grown at 37 C under 5%
CO2. Huh7.5.1 cells were cultured in DMEM medium as previously
described.63 Cells in log-phase growth were harvested by
trypsinization followed by two washing to remove all traces of
enzyme. Cells were seeded in 96-well clear, flat-bottom plate
(Corning) at a density of 5000 cells per well, and each plate was
incubated overnight at 37 C under 5% CO2. Samples dissolved in
DMSO were diluted and added to the appropriate wells to give final
concentrations of 20 and 2 mg/mL (20, 4, 0.8, 0.16, and 0.032 mM for
pure compounds) with a total volume of 100 mL and 0.5% DMSO.
The cells with the test samples were then incubated for 72 h at
37 C. Cell viability was examined using a commercial absorbance
assay (Cell titer 96 Aqueous One Solution Cell Proliferation Assay,
Promega Corp, Madison, WI). For Huh7.5.1 cells, viability was
determined by measuring ATP levels in cells using the ATPlite kit
(Perkin Elmer, Waltham, MA) as previously described.64 Results
are expressed as percent survival relative to the solvent (DMSO)
control.
4.6. Antifungal assay
The test fungal isolate Microsporum gypseum was kept at the
Fungal Culture Collection at the Department of Chemistry and Bio-
chemistry at the University of North Carolina at Greensboro. The
test isolate was maintained on Saboraud dextrose agar plates at
rt and sub-cultured monthly throughout this study. The test com-
pounds were dissolved in DMSO and 5 mL were loaded onto a 6 mm
filter paper disk to obtain the desired 25 mg sample concentration
per disk. Antimycotic activity was carried out by the agar disk dif-
fusion method.65,66 Following growth of the fungi, the conidia were
harvested in sterile distilled deionized water. The inoculum was
adjusted to 0.5–1.0 OD (105 cells/mL) at 600 nm. Mueller-Hinton
agar supplemented with 2% glucose and 0.5 mg/ml methylene blue
was then seeded with 100 lL of the inoculum. Disks impregnated
with the test agent were aseptically added onto the surface of
the inoculated plates. The sensitivity of the microorganism to the
compounds was determined after 5 d by measuring the diameter
(in mm) of the zones of inhibition around the disks.
4.7. Principal component analysis
The structures and SMILES where generated with ChemDraw
and 11 molecular properties were calculated using QikProp (ver-sion 3.5).67 The calculated properties can be divided in three main
groups: electronic, surface, and solubility descriptors. The elec-
tronic descriptors were: calculated electron affinity EA (eV), pre-
dicted polarizability (QPpolrz), electrotopological state (Estate)
and dipole moment of the molecule (dipole). The surface descrip-
tors were: total solvent accessible area (SAS), hydrophilic compo-
nent of the SASA (FISA), carbon and attached hydrogen
component of the SASA (PISA), Van der Waals surface area of polar
nitrogen and oxygen atoms (PSA), and solvent-accessible surface
area of fluorine atoms (SAFluorine). The solubility descriptors
were: free energy of solvation in hexadecane (QPlogPC16) and pre-
dicted aqueous solubility (QPlogS). To generate a visual represen-
tation of the chemical space based on these properties, a
principal component analysis was performed using Molecular
Operating Environment (version 2014.08),68 and Data Warrior
(version 4.2.2).69
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